Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

2026-02-06 - 05:37

SHANGHAI, Feb. 6, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China’s National Medical Products Administration (NMPA) has approved VELSIPITY® (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active